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It is well accepted that natural tissue regeneration is unlikely to occur if the cells are not
supplied with an extracellular matrix (ECM) substitute. With this goal, several different
methodologies have been used to produce a variety of 3D scaffolds as artificial ECM
substitutes suitable for bone and cartilage tissue engineering. Furthermore, osteochondral
tissue engineering presents new challenges since the combination of scaffolding and
co-culture requirements from both bone and cartilage applications is required in order to
achieve a successful osteochondral construct.
In this paper, an innovative processing route based on a chitosan particles aggregation
methodology for the production of cartilage and osteochondral tissue engineering
scaffolds is reported. An extensive characterization is presented including a morphological
evaluation using Micro-Computed Tomography (µCT) and 3D virtual models built with an
image processing software. Mechanical and water uptake characterizations were also
carried out, evidencing the potential of the developed scaffolds for the proposed
applications. Cytotoxicity tests show that the developed chitosan particles agglomerated
scaffolds do not exert toxic effects on cells. Furthermore, osteochondral bilayered scaffolds
could also be developed. Preliminary seeding of mesenchymal stem cells isolated from
human adipose tissue was performed aiming at developing solutions for chondrogenic and
osteogenic differentiation for osteochondral tissue engineering applications.
C© 2005 Springer Science + Business Media, Inc.
1. Introduction
Tissue engineering has developed into a multi-
disciplinary field using both the state of the art and
breakthrough research of several different areas. It uses
biological, chemical and materials engineering princi-
ples towards the repair, restoration or regeneration of
living tissues combining biomaterials, cells and bio-
logically active factors. This now well accepted con-
cept leads to the basis of one of the three key issues
in tissue engineering which is clearly the scaffolding
that should provide an ideal site for cell attachment
and proliferation leading to further tissue regeneration.
The extracellular matrix (ECM) that surrounds cells in
the body not only physically supports cells but also
regulates their proliferation and differentiation. Conse-
∗Author to whom all correspondence should be addressed.
quently scaffolds need to be developed for sustaining
in-vitro tissue reconstruction as well as for in-vivo cell-
mediated tissue regeneration. It is almost impossible to
repair tissue defects if the cells are not supplied with
such kind of an ECM substitute.
Bearing this in mind, several different methodologies
have been used to produce a variety of three dimen-
sional synthetic or naturally based scaffolds suitable for
tissue engineering applications. Researchers have been
using, for instance, injection moulding with blowing
agents [1], solvent casting and salt leaching techniques
[2] or the latter combined with compression moulding
[3] or gas foaming [4, 5]. In the salt leaching tech-
nique, the pre-incorporated salt in the polymeric matrix
is dissolved creating the pores. Fibre bonding [6] has
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also been used to produce successfully fibre meshed 3D
structures with high interconnectivity. Other techniques
such as freeze-drying [7–9] and rapid prototyping tech-
nologies [10–12] have also been used to produce inter-
esting scaffolds. Nevertheless, further research on the
scaffold design is still needed because the chemical
nature and structure of the 3D constructs significantly
affect the success of tissue engineering approaches both
in-vitro and in-vivo. Moreover, an optimal scaffold has
not been identified yet.
Towards this goal, an innovative methodology is be-
ing developed in several groups, based on the agglom-
eration of prefabricated microspheres. The technique
is generally based on the random packing of micro-
spheres with further aggregation by physical or thermal
means to create a three dimensional porous structure.
This technique is being used to construct scaffolds di-
rectly [13] or it can be proposed to be used indirectly
by producing a negative structure which will serve as a
reverse template to obtain the scaffolds.
The research group of C.T. Laurencin [13–15] have
been applying this technique for the development
of poly(lactide-co-glycolide) (PLAGA) microspheres-
based matrices for bone repair. The researchers have
tried different approaches by developing sintered mi-
crospheres based matrices [13, 14] or gel microspheres
matrices [15]. Composite microspheres containing hy-
droxyapatite were also used for the fabrication of
polymer-ceramics 3D matrices for bone applications
[16]. In the case of sintered microspheres matrices, the
microspheres are first obtained by a solvent evaporation
technique. The 3D structures are then further processed
by heating the pre-fabricated PLAGA microspheres
above the glass transition temperature. The polymer
chains are activated to interlink with neighbouring poly-
mer chains and thus form contacts between neighbour-
ing microspheres [15]. In the gel microspheres matrix
methodology, the PLAGA gel microspheres are ob-
tained by emulsion with poly(vinyl alcohol) (PVA).
The following agglomeration is based on a multiple
step production that includes air-drying, freeze-drying,
rehydration with salt leaching and freeze-drying again.
In general, microsphere based matrices show very in-
teresting properties for a possible application in bone
repair.
Another strategy that uses microspheres includes
their embedding in a hydrogel matrix [17–19]. In that
approach, the goal of incorporation of previously pro-
duced microspheres is to encapsulate either cells [20] or
biologically active factors for either favouring the cell
attachment and proliferation behaviour [18, 21–23] or
to enhance the vascularization [24].
Several million people worldwide suffer from severe
joint pain and related dysfunction, such as loss of
motion as a result of injury or osteoarthritis [25–28].
In particular, loss of function of the knees can severely
reduce mobility and thus the patient’s quality of life
[29]. The biological basis of joint problems is the dete-
rioration of articular cartilage which covers the bone at
the joint surface [30]. Current treatments most widely
used are based on autologous strategies such as mosaic-
plasty [31]. Abrasion arthroscopy, subchondral bone
drilling and microfracture typically result in fibrocar-
tilage filling the defect site [28]. Allogenic transplan-
tation of osteochondral grafts has had clinical success,
but its supply is limited and has a risk of infection or
even rejection [26, 28]. Therefore, besides bone and
cartilage tissue engineering approaches, a combination
of both as osteochondral constructs is needed in clinical
practice.
To create constructs with more favourable integra-
tive properties several researchers are exploring the de-
velopment of tissue engineered osteochondral compos-
ite constructs [26, 27, 32, 33]. However, osteochondral
tissue engineering presents new interesting challenges
because the combination of scaffolding and co-culture
requirements from both bone and cartilage applications
in an efficient way is required to achieve a successful
osteochondral approach.
A few approaches have been proposed based on the
development of bilayered 3D materials [25, 26, 32–35].
Osteochondral scaffolds based on collagen gels and cal-
cium phosphate ceramics were proposed by Tagushi
et al. [33]. The processing methodology consists of
the formation of a calcium phosphate gradient into
cartilage-like matrices containing type II collagen us-
ing a modified alternate soaking process. It was shown
that, after a number of soaking cycles, calcium phos-
phate crystals were gradiently formed from the top to
the middle of gels [33].
A very interesting work was presented by Sherwood
et al. [26] in 2002 where a three-dimensional print-
ing process was used to build a one-piece bilayered
osteochondral scaffold. The upper, cartilage region
was 90% porous and composed of D,L-PLGA/L-PLA,
with macroscopic staggered channels to facilitate ho-
mogenous cell seeding. The lower, cloverleaf-shaped
bone portion was 55% porous and consisted of a L-
PLGA/TCP composite, designed to maximize bone in-
growth while maintaining critical mechanical proper-
ties [26].
A different approach was used by Lu et al. [25, 34,
35]. They based their studies on chondrocyte encapsu-
lation in agarose hydrogels for the cartilage component,
and composites microspheres (PLAGA and Bioactive
Glass©R ) prepared by a water-oil-water emulsion and
further sintered to produce the 3D scaffolds for the bone
component. These studies showed that chondrocytes
maintained their phenotype and developed a functional
extracellular matrix. In addition, the osteochondral con-
struct was found to be capable to simultaneously sup-
port the growth of multiple matrix zones. Recently, this
research group has also presented a multi-phased com-
posite scaffold for soft tissue-to-bone interface [34] us-
ing 3 different phases composed by PLAGA woven
mesh, PLAGA microspheres and PLAGA—Bioactive
Glass©R microspheres. Studies were undertaken with os-
teoblasts and fibroblasts to evaluate the potential of sup-
porting multiple cell types and the scaffold was used as
a model system to regenerate soft tissue to bone inter-
face.
In the present paper, a new processing route based
on chitosan particles aggregation is described for
the production of cartilage and osteochondral tissue
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engineering scaffolds. The described method uses
previously prepared chitosan-based particles. For the
osteochondral approach, bilayered scaffolds were
developed in order to achieve an improved in-
tegrative bone and cartilage interface needed for
these applications. Preliminary cell tests were per-
formed by seeding mesenchymal stem cells iso-
lated from human adipose tissue on the scaffolds
and trying to promote them both in chondrogenic
and osteogenic differentiation. This is a prerequi-
site for cartilage and osteochondral tissue engineering
applications.
2. Materials and methods
2.1. Scaffolds production
Chitosan (from Sigma-Aldrich, medium molecular
weight and 87.8% of deacetylation degree) was grinded
and dissolved overnight in acetic acid (1% vv) to obtain
a chitosan solution (2% wt). Unless otherwise stated,
all chemicals were bought from Sigma-Aldrich and
used as received. In composite particles production for
the osteochondral bilayered scaffolds, 20% wt of non-
sintered hydroxylapatite (HA) (CAM Implants, UK)
with an average particle size of 6 µm [36] was ho-
mogeneously dispersed in the chitosan solution. Af-
ter complete dissolution and filtration, the prepared
solutions were extruded trough a syringe at constant
rate (10 ml/h) to form chitosan droplets into a NaOH
(1 M) precipitation bath where particles with regular
diameter were formed. The chitosan particles were left
overnight in the precipitation bath and then repeat-
edly washed with distilled water. For the production
of the bilayered scaffolds, the composite particles were
submitted to a crosslinking reaction with glutaralde-
hyde. Further information on this can be found else-
where [37, 38]. The particles were subsequently pressed
into moulds and left to dry in an oven at 50 ◦C for
3 days. Cylinder shaped scaffolds with 8 mm height
and 5 mm in diameter were obtained. A schematic
representation of the used methodologies is shown in
Fig. 1.
Figure 1 Schematic representation of the chitosan precipitation and particle aggregation methodologies.
2.2. Scaffolds characterization
The scaffolds morphology was analyzed by Scanning
Electron Microscopy (SEM) in a Leica-Cambridge
S-360 (Leica-Cambridge, UK) microscope equipped
with V03.02A software. Micro-Computed Tomogra-
phy (µ-CT) evaluation of the scaffolds was carried
out using a Scanco 20 equipment (Scanco Medicals,
Switzerland). X-ray scans were performed in high res-
olution mode (9 µm) and 240 slices of the scaffolds
were obtained. The 2-D histomorphometric analysis of
the scaffolds was performed using a threshold 51 to
identify the polymeric phase in order to determine the
mean porosity as well as the porosity distribution along
the scaffold (from 0 to 2000 µm). Furthermore, with
the µ-CT data import and MIMICS©R (Materialise Inter-
active Medical Image Control System) image process-
ing software (Materialise, Belgium), it was possible to
build 3D virtual models representing the morphological
structures of the scaffolds.
The mechanical properties of the developed scaffolds
were tested on a compressive solicitation mode in an
Instron Universal Mechanical Testing machine in a con-
trolled environment (23 ◦C/55% RH). The cross-head
speed used was 2 mm/min.
The hydration behaviour was assessed in media with
different pH (5, 7.4 (physiological pH) and 9) in order
to study the potential responsive behaviour of the de-
veloped systems. The assays were performed at physio-
logical temperature (37 ◦±1 ◦C) for predetermined im-
mersion periods up to 14 days. The swelling profile was
characterized using the following equation:
% Hydration degree = [(Ww − Wi)/Wi] × 100 (1)
where Wi is the initial weight and Ww is the wet weight
at determined test period.
2.3. In-vitro biological testing
The cytotoxicity of the material was assessed by eval-
uating cellular viability using MTS assay (3-(4,5-di-
methylthiazol-2-yl)-5-(3-carboxylmethoxyphenyl)-2-
(4-sulfophenyl)-2H tetrazolium) (Cell Titer 96©R
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AQueous Solution Cell Proliferation Assay, G3580,
Promega, USA). For this purpose, materials were
incubated in culture medium for 24 h at 37 ◦C with
constant shaking. Latex was also incubated as a posi-
tive control. Cultured cells (L929 fibroblasts cell line)
were plated (200 µl/well) into 96-well micrometer
plates at 6.6×104 cells/well. The plates were incubated
for 24 h at 37 ◦C in a humidified atmosphere of 5%
CO2 in air. After that, the medium was replaced by the
previously prepared material extracts, using culture
medium as a negative control. After a 72 h incubation,
the cell culture was treated with MTS (in medium
without phenol red) and incubated for further 3 h
at 37 ◦C in a humidified atmosphere of 5% of CO2
in air. At this stage, culture medium with MTS was
transferred to new wells. The optical density (OD)
which is directly proportional to the cellular activity
(it reflects the mitochondrial activity) was read on a
multiwell microplate reader (Synergy HT, Bio-Tek
Instruments) at 490 nm.
For the preliminary osteogenic and chondrogenic
differentiation studies the scaffolds were seeded with
mesenchymal stem cells (MSC) isolated from adipose
tissue derived from liposuction procedures as previ-
ously described [39]. Briefly, the liposuction material
was washed 3 times with phosphate buffered saline
(PBS purchased from PAA, Austria) to remove most
of the blood and tumescence solution. Afterwards the
tissue was digested in PBS buffered with 25 mM
Hepes (PAA, Austria) containing 1.5 mg/mL colla-
genase (Biochrom, Germany) and 20 mg/mL bovine
serum albumine (PAA, Austria) at 37 ◦C under vigorous
shaking for 1 h. To eliminate red blood cells the isolated
fraction was incubated with erythrocyte lysis buffer
consisting of 154 mM NH4Cl, 10 mM KHCO3 and 0.1
mM EDTA for 10 min at 37 ◦C. After several washing
and centrifugation steps the cells were filtered through a
100 µm filter and cultured in DMEM/Ham’sF12 (1:1),
10% FCS, 2 mM L-glutamine, 100 U/mL penicillin
and 100 µg/mL streptomycin at 37 ◦C and 5% CO2 in
a water-saturated atmosphere. All cell culture reagents
were purchased from PAA, Austria if not otherwise
stated. Subculturing was performed before the cells
reached confluence. Cells from passages 2 to 4 were
used for the cell seeding experiments.
For this purpose, 5 × 105 cells were seeded onto
each scaffold which were then cultured in control, os-
teogenic and chondrogenic medium, respectively. Os-
teogenic medium consisted of DMEM (1 g/L glu-
cose), 10% FCS, 2 mM L-glutamine, 100 U/mL
penicillin and 100 µg/mL streptomycin as well as
0.1 µM dexamethasone (Sigma, Austria), 50 µM
ascorbate-2-phosphate (Fluka, Switzerland), 10 mM β-
glycerophosphate (Sigma, Austria) and 10 nM 1α,25-
dihydroxyvitamin D3 (Fluka, Switzerland). Chondro-
genic medium was comprised of DMEM (1 g/L glu-
cose), 10% FCS, 2 mM L-glutamine, 100 U/mL peni-
cillin and 100 µg/mL streptomycin as well as 0.1 µM
dexamethasone, 0.15 µM ascorbate-2-phosphate, 1%
insulin-transferrin-selenium supplement (100×, Invit-
rogen, Austria), 40 µM L-proline (Sigma, Austria)
and 10 ng/ml TGF-β1 (PromoKine, Germany). After 2
weeks of incubation samples were prepared for SEM
observation by washing the seeded scaffolds 3 times in
pre-warmed PBS, fixing them in 2.5% glutaraldehyde
at 4 ◦C for 30 min and washing them again 2 times with
PBS. Then the samples were dehydrated in increasing
concentrations of ethanol (50, 70, 90 and 100%), each
step lasting 30 min. After air-drying the samples were
incubated two times for 15 min in hexamethyldisilazane
(Sigma, Austria).
The supernatant was harvested on day 7 and 14
for ALP activity determination using previously estab-
lished protocols. In brief, 3 volumes of substrate so-
lution consisting of 1 M diethanolamine-hydrochloric
acid buffer with 0.2% p-nitrophenylphosphate at pH 9.8
were thoroughly mixed with the culture supernatant.
After 45 to 60 min incubation at 37 ◦C 4 volumes of
2 M NaOH and 0.2 mM EDTA were added to stop the
enzymatic reaction. Immediately, the samples as well
as serial dilutions of the standard p-nitrophenol rang-
ing from 0 to 20 mmoL/L were measured in triplicate
in a microplate reader (Amersham Biosciences, UK)
at 405 nm. Concentrations were calculated using a 4-
parameter fit curve. All reagents used for the ALP assay
were purchased from Sigma, Austria.
Additionally, seeded wells without scaffolds were
also incubated for 2 weeks with control, osteogenic
and chondrogenic medium, respectively and stained
with Von Kossa or Alcian Blue to detect osteogenic and
chondrogenic differentiation in a 2D environment. For
Von Kossa staining, the cells were fixed for 30 min with
10% neutral-buffered formalin. After rinsing with dis-
tilled water cells were overlaid with 5% silver nitrate
for 30 min. Staining was developed with 5% sodium
carbonate in 25% neutral-buffered formalin and fixed
by a 5 min incubation with 5% sodium thiosulphate.
For Alcian Blue staining cells were rinsed with PBS
and stained for 30 min at room temperature with 1%
Alcian Blue in 3% acetic acid at pH 2.5.
3. Results and discussion
3.1. Scaffolds morphological and
mechanical characterization
Using the particle aggregation method, it was possi-
ble to obtain chitosan-based scaffolds with very inter-
esting properties. The obtained chitosan particles are
characterized by a smooth surface and uniform spher-
ical shape with a mean diameter of 500–800 µm con-
firmed by SEM microphotographs (Fig. 2(A)). After
press-fitting into specific moulds and drying, chitosan
scaffolds could be obtained with a mean pore diame-
ter ranging from 100 to 400 µm with a typical pore
morphology shown in Fig. 2(B). However, the over-
all random packing of the chitosan particles into the
3D scaffold structures shown in the cross-section (Fig.
2(C)) clearly influenced the nature of the pores.
Fig. 2(C) shows the interconnectivity and three-
dimensional structure of the developed chitosan scaf-
folds. The bonding of the chitosan particles was
achieved due to the bioadhesive character of the chi-
tosan polymer that resulted in the union of adja-
cent particles at their contact points to form the chi-
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Figure 2 SEM micrographs of chitosan particles obtained by precipitation method (A); pore morphology in the chitosan scaffolds (B); cross-section
of chitosan scaffolds obtained by the particle aggregation method (C); and interface between the chitosan particles after production of the scaffolds
(D).
tosan porous matrices (Fig. 2(D)). The scaffold’s cross-
sections (Fig. 2(C)) indicate the bonding areas by the
flat planes on the particle surfaces. This chitosan par-
ticle bonding leads to a very stable interface between
the particles which assure the mechanical integrity of
the developed scaffolds. Concerning the compressive
properties, scaffolds have shown a very good mechani-
cal behaviour compared to the typical mechanical prop-
erties obtained for chitosan based porous materials. For
the polymeric scaffolds, a high compressive modulus
of 132±7 MPa was obtained. Furthermore, it is impor-
tant to keep in mind that the mechanical properties may
be further increased when the scaffolds are crosslinked
or a ceramic filler is incorporated.
SEM of relevant cross-sections (Fig. 2(C)) and µ-CT
analysis confirmed the formation of pores in the bulk of
chitosan porous materials evidencing the scaffolds in-
terconnectivity. The 2D histomorphometric analysis al-
lowed for the characterization of the degree of porosity
and pore distribution throughout the developed scaf-
folds as presented in Fig. 3. The developed scaffolds
presented a mean porosity of about 30% (well dis-
tributed throughout the scaffold). In spite of the fact that
many researchers are looking for scaffolds with much
higher pore volumes, there is a compromise between
the porosity and mechanical properties. In fact, for par-
ticles/microspheres agglomerated scaffolds it has been
demonstrated that interconnected structures with a pore
volume of at least 30% and a pore size of at least 100
µm are appropriate for cell ingrowth [13–15]. The main
issue seems to be to assure a proper interconnectivity.
MIMICS©R (Materialise Interactive Medical Image
Control System) is an image processing software and,
in spite of being designed as an interface software for
CT/MRI data and rapid prototyping machines, it can
be very useful for the morphological characterization
of scaffolds. MIMICS©R enables µ-CT data import and
Figure 3 2D histomorphometric analysis of mean porosity (—) and pore
distribution throughout the developed scaffolds.
with the segmentation, thresholding and visualization
tools allows for the construction of accurate 3D virtual
models of the developed scaffolds as shown in Fig. 4.
3.2. Water uptake behaviour at different ph
Concerning the water uptake, we observed a pH depen-
dent behaviour of the developed scaffolds. In general,
the degree of swelling of chitosan based materials is
very high at pH 5 compared to pH 7.4 and 9. This is
due to the inherent hydrophobicity of chitosan dom-
inating at high pH values. In polymeric scaffolds, a
hydration equilibrium of 160–175% (depending on the
pH of the medium) was reached after 8 days of immer-
sion in different aqueous media as shown in Fig. 5. The
swelling degree curve at pH 5 begins to decline after
day 3, showing that the dissolution tendency exceeds
the swelling degree (Fig. 5). This may be due to the
protonation of the NH2 groups in the acidic medium.
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Figure 4 Different perspectives of 3D virtual models of the developed chitosan scaffolds produced by particle aggregation.
Figure 5 Water uptake behaviour of the chitosan porous scaffolds at
different pH.
However, and if desirable, this behaviour can be con-
trolled by means of a crosslinking reaction where the
dissolution is prevented by the reaction of the reactive
NH2 groups with glutaraldehyde. This pH dependent
behaviour will be very useful in a scaffold that should
also exhibit controlled release of a desired biologically
active agent at the implantation site, especially when
considering the decrease of pH that is observed in-vivo
due to the inflammatory response. Therefore, it might
be very useful that the main mechanism which con-
trols the release observed for chitosan based materials
is their respective water uptake behaviour.
3.3. Cytotoxicity tests
MTS tests were performed in order to assess the po-
tential cytotoxicity of the developed scaffolds. It was
verified that extracts from the chitosan based scaffolds
shown did not affect the cellular viability, since a similar
cellular viability was obtained in the controls (culture
medium). The MTS results are plotted in Fig. 6.
Figure 6 Cytotoxicity of the developed chitosan (Ch) scaffolds evalu-
ated by MTS assay of 6.6 × 104 cells incubated with extracts of the
scaffolds.
Figure 7 Photograph showing the developed bilayered chitosan scaf-
folds.
3.4. Osteochondral bilayered scaffolds
To create constructs having more favourable integra-
tion properties that might be used for osteochondral
tissue engineering applications, we have also investi-
gated osteochondral composite porous materials devel-
opment. Bilayered scaffolds were successfully devel-
oped by means of aggregating polymeric and compos-
ite chitosan-based particles. Fig. 7 shows the typical
scaffolds obtained with this methodology.
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Figure 8 SEM micrographs showing the interface between chitosan particles (A) and scaffolds components (B) obtained using fibrin glue.
Figure 9 Stereolight photographs showing the interface between both scaffolds components using chitosan glue (brighter area).
Furthermore, the simplest strategy to obtain osteo-
chondral constructs, especially when aiming at mini-
mizing complex co-culture procedures seems to be to
culture both components of the scaffolds in their own
separated differentiation media and, at a later stage, try
to bond the polymeric (cartilage part) and composite
(bone part) chitosan-based layers by using e.g. a tissue
adhesive. The most widely used tissue sealant is fibrin
glue due to its biocompatibility and adhesive proper-
ties [40, 41]. Furthermore, this material was already
successfully used in the repair of chondral and osteo-
chondral injuries [42]. Studies were carried out using
different concentrations of thrombin in order to achieve
appropriate viscosity and coagulation time. The ade-
quate thrombin concentration was found to be 4 I.U./ml
accomplishing the bonding of both scaffold compo-
nents in aqueous solution for short immersion periods.
The fibrin glue approach has shown to be effective in
the bonding of chitosan particles as demonstrated in
Fig. 8(A). The bridging created by fibrin allows indeed
this particle-linking. Particles exhibit a high compati-
bility with this sealant. However, for longer immersion
periods or after drying, the linkage stability was found
to be rather poor leading to the dissociation of both
components as shown in Fig. 8(B).
In order to solve this problem, another bonding strat-
egy was followed using a highly viscous chitosan so-
lution as an adhesive layer. As it was already referred,
chitosan polymers present very good bioadhesive prop-
erties. In fact, with this approach it was possible to ac-
complish the bonding between both particles and com-
ponents with additional high material compatibility. By
SEM observation it was not possible to detect the chi-
tosan glue which reveals the high compatibility between
the glue and the scaffolds. Stereolight microscopy was
used to identify the scaffolds interface when using the
chitosan glue. The chitosan glue can be identified by the
brighter area in the interface of the scaffolds as shown
in Fig. 9. One interesting feature is that this approach
does not compromise the scaffolds interconnectivity at
the interface, since the bonding sites are still the con-
tact points of adjacent particles where the adhesive is
present. This strategy does not create any interface bar-
rier area allowing further cell migration and nutrients
flow. One can conclude that a successful adhesion was
achieved by means of using a chitosan glue to assemble
the polymeric and composite layers in order to fabricate
an osteochondral scaffold.
3.5. Cell seeding and differentiation
Such tissue engineered constructs may provide an
alternative clinical option for the currently used autol-
ogous transplantation of mature tissue which is associ-
ated with high donor site morbidity. For this purpose,
a suitable cell source would likely have to be incor-
porated into the construct design. First experiments of
seeding porous chitosan scaffolds with mesenchymal
stem cells isolated from adipose tissue were performed.
The preliminary results obtained are very promising as
in the seeded scaffolds some events occurred which
may indicate an osteogenic and chondrogenic differen-
tiation. In contrast, no events of osteogenic or chon-
drogenic differentiation in the control wells without
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Figure 10 SEM microphotographs showing the morphological difference of cells isolated from adipose tissue, seeded on chitosan particle agglom-
erated scaffolds and cultured for 2 weeks under chondrogenic (A, B) and osteogenic (C, D) conditions, respectively.
the scaffolds (2D cultures) were detected in this short
time frame, as confirmed also by Von Kossa and
Alcian Blue staining, respectively. This may propose
an influence of the 3D support provided by the scaf-
folds on the differentiation ability of the cells indicated
by a change in cell morphology shown by SEM analysis
(Fig. 10). Hence, mesenchymal stem cells isolated from
adipose tissue, seeded on the scaffolds and cultured
with chondrogenic medium had a rounded shape which
is a morphological prerequisite for chondrogenic differ-
entiation (Fig. 10(A) and (B)). The ones cultured with
osteogenic medium had a flattened morphology and
showed bridging between the chitosan particles which
might suggest a differentiation along the osteogenic
lineage (Fig. 10(C) and (D)). Similar attachment be-
haviour has been observed by Borden et al. [13] who
seeded primary human osteoblasts in PLAGA-based
microspheres sintered scaffolds. The assumption that
the cells had in fact differentiated into mature cell types
might be corroborated by ALP activity measurements
which showed very low levels when cultured in chon-
drogenic medium (data not shown). On the contrary,
scaffolds seeded with cells and incubated in osteogenic
medium showed a very high ALP activity compared to
the controls cultured without osteogenic supplements.
However, future work will focus on the detection of
specific markers on the molecular as well as the protein
level to confirm these results.
4. Conclusions
By means of using a particle aggregation method, it
was possible to obtain chitosan-based scaffolds with
very promising properties for the use in cartilage and
osteochondral applications. µ-CT and MIMICS©R could
be successfully used for the morphological character-
ization of the developed scaffolds. Scaffolds have a
mean porosity of 30% with pores ranging from 100 to
400 µm well distributed throughout the scaffolds and
clearly interconnected. The developed scaffolds seem
to be very adequate for cell ingrowth. In addition, and
due to its low pore volume, there is no compromising of
the typical mechanical properties of the particle based
scaffolds. The developed scaffolds demonstrate no cy-
totoxicity as evaluated by the MTS assay. Furthermore,
very promising osteochondral bilayered scaffolds could
also be developed. A simple strategy is also presented
based on the use of a material adhesive for obtain-
ing bilayered scaffolds. Preliminary cell seeding and
differentiation tests with mesenchymal stem cells iso-
lated from adipose tissue were carried out, indicating
cells with osteogenic and chondrogenic morphology in
the 3D particle agglomerated scaffolds. Although this
needs to be further investigated it is a very promising
indicator for the use of the developed scaffolds in the
proposed osteochondral applications.
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